Financial Position - Total assets increased to ¥5,685,463,995.12, up from ¥3,848,818,212.18, representing a growth of approximately 47.8%[25] - Current assets totaled ¥3,771,343,234.56, compared to ¥1,807,735,806.76 in the previous period, indicating a rise of about 108.5%[25] - Non-current assets decreased to ¥1,914,120,760.56 from ¥2,041,082,405.42, reflecting a decline of approximately 6.2%[25] - The total assets of Hubei Hongyuan Pharmaceutical Technology Co., Ltd. reached CNY 5,709,791,741.00 as of June 30, 2023, compared to CNY 3,874,152,752.16 at the end of the previous period[47] - The company's non-current assets totaled CNY 2,160,590,689.47, slightly down from CNY 2,209,229,490.49[47] - The total owner's equity at the end of the period was 352,749,600.00 RMB[81] - The total equity attributable to owners is 756.00 million RMB, reflecting a stable financial position[84] Cash Flow and Investments - The company reported a net cash outflow from investing activities of ¥1,845,985,184.25, compared to a net outflow of ¥231,474,524.37 in the previous period[29] - Cash and cash equivalents at the end of the period were ¥60,035,607.52, down from ¥309,451,948.16, a decrease of about 80.6%[29] - The company reported an investment loss of -6,553,228.17, a significant drop from the previous period's gain of 143,114,763.04[53] Liabilities - The total liabilities included short-term borrowings of ¥7,630,072.00, with accounts payable at ¥320,153,389.92, down from ¥417,543,545.94, a decrease of about 23.3%[25] - The total liabilities include short-term borrowings of CNY 17,642,065.09 and accounts payable of CNY 359,968,710.88[47] - The company reported a decrease in accounts payable from CNY 456,605,437.21 to CNY 359,968,710.88, indicating a reduction of approximately 21.2%[47] Profit and Loss - The net profit for the current period is 65,023,439.88, a decrease from 302,536,958.56 in the previous period, representing a decline of approximately 78.5%[51] - The total profit for the current period is 76,092,913.33, down from 333,497,999.30, indicating a decrease of about 77.2%[51] - The basic earnings per share decreased to 0.1709 from 0.7949, a decline of approximately 78.5%[51] - The total comprehensive income attributable to the parent company's owners is 65,023,439.88, down from 302,536,958.56, reflecting a decrease of about 78.5%[51] Expenses - Research and development expenses increased to 26,571,327.70 from 25,925,032.70, reflecting a rise of approximately 2.5%[50] - The interest expense for the current period is 5,296,841.83, significantly higher than 1,314,854.87 in the previous period, marking an increase of about 302.5%[50] - The sales expenses for the current period are 17,863,131.92, slightly down from 18,136,364.40, indicating a decrease of about 1.5%[50] - The tax expenses for the current period are 11,069,473.45, compared to 30,961,040.74 in the previous period, showing a decrease of approximately 64.3%[50] Shareholder Information - The company’s major shareholders include Yan Xiaohui with 22.15% and Yin Guoping with 16.04% of shares[17] - The company has a total of 352,749,600 shares, with 102,986,836 shares held by other pre-IPO shareholders[37] Corporate Governance - The company did not report any significant legal disputes or contingent liabilities during the reporting period[5] - There were no significant changes in the company’s registered address or contact information during the reporting period[27] - The company has not undergone an audit for the semi-annual financial report[45] - The report indicates that the company has terminated its listing on the National Equities Exchange and Quotations system as of February 21, 2023[35] Future Outlook and Strategy - The company has not disclosed any new product developments or market expansion strategies in the report[49] - The company is focusing on the development of new products and technologies to enhance its market position[97] - The company is actively exploring market expansion strategies to increase its market share in the pharmaceutical sector[97] - The company plans not to distribute cash dividends or issue bonus shares, indicating a focus on reinvestment[95] Accounting Policies - The financial statements were prepared based on the going concern assumption in accordance with the relevant accounting standards[83] - The financial statements are prepared based on the accrual basis of accounting, ensuring accurate representation of financial performance[99] - The financial report includes specific accounting policies and estimates, ensuring compliance with relevant accounting standards[124] Risk Management - The company has not reported any significant risks that could impact its operations in the near term[94] - The company has confirmed its ability to continue as a going concern for at least the next 12 months[100]
宏源药业(301246) - 2023 Q2 - 季度财报